News for CVLB Stock

Conversion Labs to Present at the LD 500 Virtual Investor Conference on Sept. 1, 2020 Conversion Labs Reverse Splits Common Shares 1-for-5 in Preparation for Nasdaq Listing Conversion Labs Expects Q3 2020 Record Revenue of $11.2 Million, up 254%; Subscription ARR Hits $19.3 million, up 458% Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021 Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer Conversion Labs Increases Stake in Fast-Growing SaaS Subsidiary Conversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer Conversion Labs to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021 Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer Conversion Labs Annualized Revenue Run-Rate Hits $53.9 Million, up 332% vs. 2019, Driven by Subscriptions to an Expanding Suite of Telehealth Brands Conversion Labs Launches Veritas MD™ Telehealth Platform, Delivering Greater Access to Growing Portfolio of Industry-Leading, Direct-to-Consumer Pharmacy and Wellness Brands